SSR Miningの空売り状況は、投資家がSSR Miningの株価下落に賭けている度合いを知ることができます。空売りデータは2週間ごとに更新されます。

SSR Mining (NASDAQ:SSRM) 株価情報, 空売り情報

SSR Mining

SSR Mining Inc is a minerals company focused on mining precious metals in the Americas. More than half of Silver Standard's revenue is attributable to the production of gold, with a key portion derived from silver production. The company owns and operates the Marigold mine in Nevada, United States; the Seabee Gold Operation in Saskatchewan, Canada; and the Puna mine in Argentina. The majority of gold production is derived from the Marigold mine, and Silver Standard's silver production is principally derived from the Puna mine.

SSR Mining Inc

News

Guidance

KVUE

Kenvue Sees FY25 Sales Growth Of (-1)% - +1%; Adj EPS Growth Of 0% - +2%

Advanced Drainage Systems Approved Quarterly Cash Dividend Of $0.16 Per Share, A 14% Increase Over The Prior Year Dividend Amount; Dividend Is Payable On  March 14

The Board of Directors of CMS Energy today increased the quarterly dividend on the company's common stock to 54.25 cents per share, up from 51.50 cents per share.&nbsp;
Based on Wednesday's closing price for CMS Energy common stock, $67.12, the dividend represents an annualized yield of 3.2 percent.
The first quarter dividend for the common stock (CUSIP: 125896100) is payable Feb. 28, 2025, to shareholders of record Feb. 17, 2025.

Dividends

CMS Energy Increases Quarterly Dividend To 54.25 Cents From 51.50 Cents Per Share, Payable February 28

2025 Full-Year Financial Outlook Summary The company expects net sales growth of at least 2%, driven primarily by net price realization. Reported earnings per share is expected to be down in the high-40% range as higher commodity costs, rebased incentive compensation, and a higher economic tax rate are expected to more than offset price realization, productivity and cost savings programs.&nbsp; The company projects adjusted earnings per share to be down in the mid-30% range when excluding one-time costs associated with cost savings initiatives and acquisition integration activities.&nbsp; The gap between the reported and adjusted earnings per share growth outlooks primarily reflects a large derivative mark-to-market gain recorded in reported earnings per share in 2024.
<figure class="table"> 
<table>
<tbody>
<tr>
<td colspan="1" rowspan="1">2025 Full-Year Outlook</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">Total Company</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Net sales growth4</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">At least 2%</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Reported earnings per share growth</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">Down high-40% range</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Adjusted earnings per share growth</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">Down mid-30% range</td>
</tr>
</tbody>
</table>
</figure><figure class="table"> 
<table>
<tbody>
<tr>
<td colspan="1" rowspan="1">4 The impact of the Sour Strips acquisition is anticipated to be an approximate 30 basis point benefit to net sales growth for the full-year 2025. Additionally, the impact of foreign currency exchange rates is anticipated to be an approximate 30 basis point headwind to net sales growth for the full-year 2025.</td>
</tr>
</tbody>
</table>
</figure>
The company also expects:
<ul>
<li>A reported and adjusted effective tax rate in the range of approximately 14% to 15%;</li>
<li>Other expense, which primarily reflects the write-down of equity investments that qualify for a tax credit, of approximately $170 million to $180 million;</li>
<li>Interest expense of approximately $190 million to $195 million, reflecting a higher interest rate environment;</li>
<li>Capital expenditures of approximately $425 million to $450 million, as capital spending as a percentage of sales returns to historical levels; and</li>
<li>Advancing Agility &amp; Automation Initiative savings of approximately $125 million.</li>
</ul>

Hershey Sees FY2025 GAAP EPS $5.54-$5.86 vs $7.80 Est

Leerink Partners analyst Puneet Souda downgrades Hologic (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HOLX#NASDAQ">HOLX</a>) from Outperform to Market Perform and lowers the price target from $80 to $75.

Downgrades

Price Target

Analyst Ratings

HOLX

Leerink Partners Downgrades Hologic to Market Perform, Lowers Price Target to $75

Advanced Drainage Systems Reiterates FY25 Net Sales Outlook Of $2.90B-$2.975B Vs. $2.93B Estimate

GOOS

Canada Goose Lowers FY25 Non-IFRS Adj. EBIT Margin Guidance From +60 Basis Points To -60 Basis Points To Range Of Flat To -100 Basis Points; Lowered Non-IFRS Adj. EPS Growth Guidance From Mid-Single Digit Increase To Low-Single Digit Increase To Flat

Hershey Sees FY2025 Adj EPS $6.00-$6.18 vs $7.36 Est

Needham analyst Quinn Bolton maintains SiTime (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SITM#NASDAQ">SITM</a>) with a Buy and raises the price target from $225 to $250.

SITM

Needham Maintains Buy on SiTime, Raises Price Target to $250

Kenvue (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KVUE#NYSE">KVUE</a>) reported quarterly adjusted earnings of $0.26 per share which met the analyst consensus estimate. This is a 16.13 percent decrease over earnings of $0.31 per share from the same period last year. The company reported quarterly sales of $3.66 billion which missed the analyst consensus estimate of $3.77 billion by 2.75 percent. This is a 0.11 percent decrease over sales of $3.67 billion the same period last year.

Earnings

Earnings Misses

Kenvue Q4 Adj $0.26, Inline, Sales $3.66B Miss $3.77B Estimate

Biotech

Large Cap

Health Care

General

Eli Lilly Expects 2025 Adjusted EPS Of $$22.50-$24.00. Versus Consensus Of $12.64

Merck Initiates waveLINE-010, A Pivotal Phase 3 Clinical Trial Evaluating Zilovertamab Vedotin Combination For Treatment Of Patients With Previously Untreated Diffuse Large B-Cell Lymphoma

Rithm Capital (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RITM#NYSE">RITM</a>) reported quarterly earnings of $0.60 per share which beat the analyst consensus estimate of $0.44 by 36.36 percent. This is a 17.65 percent increase over earnings of $0.51 per share from the same period last year. The company reported quarterly sales of $490.26 million which beat the analyst consensus estimate of $480.18 million by 2.10 percent. This is a 7.91 percent increase over sales of $454.32 million the same period last year.

Earnings Beats

RITM

Rithm Capital Q4 Adj EPS $0.60 Beats $0.44 Estimate, Sales $490.26M Beat $480.18M Estimate

Tapestry (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TPR#NYSE">TPR</a>) reported quarterly earnings of $1.39 per share which missed the analyst consensus estimate of $1.75 by 20.57 percent. This is a 14.72 percent decrease over earnings of $1.63 per share from the same period last year. The company reported quarterly sales of $2.20 billion which beat the analyst consensus estimate of $2.11 billion by 4.30 percent. This is a 5.52 percent increase over sales of $2.08 billion the same period last year.

Tapestry Q2 2025 Adj EPS $1.39 Misses $1.75 Estimate, Sales $2.20B Beat $2.11B Estimate

The midpoint represents approximately 32% growth compared to 2024, driven by new Lilly medicines such as Zepbound, Mounjaro, Jaypirca, Ebglyss, Omvoh and Kisunla; approvals of new indications for existing Lilly medicines; launches of Mounjaro in additional worldwide markets; and potential launches of new medicines such as imlunestrant for metastatic breast cancer. The company continues to invest heavily in increasing manufacturing capacity and estimates producing at least 1.6 times the amount of salable incretin doses in the first half of 2025, compared to the first half of 2024.&nbsp;

Eli Lilly Expects 2025 Sales Of $58B-$61B Versus Consensus Of $45.03B

JP Morgan analyst Samik Chatterjee initiates coverage on Jamf Holding (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JAMF#NASDAQ">JAMF</a>) with a Overweight rating and announces Price Target of $20.

Initiation

JAMF

JP Morgan Initiates Coverage On Jamf Holding with Overweight Rating, Announces Price Target of $20

Darling Ingredients (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DAR#NYSE">DAR</a>) reported quarterly earnings of $0.63 per share which beat the analyst consensus estimate of $0.51 by 23.53 percent. This is a 21.15 percent increase over earnings of $0.52 per share from the same period last year. The company reported quarterly sales of $1.42 billion which missed the analyst consensus estimate of $1.45 billion by 2.38 percent. This is a 12.21 percent decrease over sales of $1.61 billion the same period last year.

Darling Ingredients Q4 2024 GAAP EPS $0.63 Beats $0.51 Estimate, Sales $1.42B Miss $1.45B Estimate

XPO (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XPO#NYSE">XPO</a>) reported quarterly earnings of $0.89 per share which beat the analyst consensus estimate of $0.63 by 41.27 percent. This is a 15.58 percent increase over earnings of $0.77 per share from the same period last year. The company reported quarterly sales of $1.921 billion which missed the analyst consensus estimate of $1.922 billion by 0.06 percent. This is a 0.98 percent decrease over sales of $1.940 billion the same period last year.

XPO Q4 2024 Adj. EPS $0.89 Beats $0.63 Estimate, Sales $1.921B Miss $1.922B Estimate

Needham analyst Mike Cikos reiterates Dynatrace (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DT#NYSE">DT</a>) from Hold to Hold.

Reiteration

Needham Reiterates Hold on Dynatraceto Hold

Eli Lilly (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>) reported quarterly earnings of $5.32 per share which beat the analyst consensus estimate of $4.94 by 7.69 percent. This is a 113.65 percent increase over earnings of $2.49 per share from the same period last year. The company reported quarterly sales of $13.53 billion which missed the analyst consensus estimate of $13.57 billion by 0.28 percent. This is a 44.69 percent increase over sales of $9.35 billion the same period last year.

Eli Lilly Q4 2024 Adj EPS $5.32 Beats $4.94 Estimate, Sales $13.53B Miss $13.57B Estimate

SSR Mining (TSE:SSRM) has released an update. SSR Mining Inc. celebrates a major milestone as its Marigold Mine hits the 5 million ounces gold prod...

SSR Mining Achieves Milestone in Gold Production

Palm Valley Capital Fund Q4 2024 Commentary

Gold Mining Stocks: Winners And Losers At The Start Of 2025

In a report released today, Ovais Habib from Scotiabank maintained a Hold rating on SSR Mining (SSRM – Research Report), with a price target of C$1...

Scotiabank Remains a Hold on SSR Mining (SSRM)

Scotiabank raised the firm's price target on SSR Mining (SSRM) to C$12 from C$10 and keeps a Sector Perform rating on the shares. Published first o...

SSR Mining price target raised to C$12 from C$10 at Scotiabank

SSR Mining cites design flaw in Copler heap leach failure

An update from SSR Mining ( ($TSE:SSRM) ) is now available. SSR Mining Inc. has announced that it will release its fourth quarter and full-year 202...

SSR Mining to Release 2024 Financial Results and Announce 2025 Guidance Post-Acquisition

SSR Mining ( ($TSE:SSRM) ) just unveiled an announcement. SSR Mining announced the appointment of Laura Mullen to its Board of Directors, effective...

SSR Mining Strengthens Board with New Appointment

RBC Capital upgraded SSR Mining (SSRM) to Sector Perform from Underperform with a price target of $8, up from $5.50. The firm says rising prices an...

Comments

SSR Mining

空売り

SSR Mining (NASDAQ:SSRM) 株価情報, 空売り情報

ニュース

パートナーシップ

ベンジンガ・グローバル